Hormonal
Discontinuation of GLP-1 receptor agonist therapy leads to substantial weight regain, indicating that obesity requires long-term, possibly lifelong, pharmacological management.
If you stop taking GLP-1 medications like semaglutide, you will likely regain most of the weight you lost. This is because obesity is a chronic condition, and the medication helps manage the underlying hormonal drivers. To keep the weight off, you likely need to stay on the medication long-term, similar to how blood pressure medication is used for hypertension.
STEP-4 trial... showing that continued semaglutide therapy prevented weight regain, while participants switched to placebo regained two-thirds of their prior weight loss within 48 weeks.
Why this rating
Based on the STEP-4 trial, a large RCT specifically designed to test weight maintenance.
Source
GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW
Natalia Strumnik et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.3(47).2025.3723
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →